Anteris Technologies logs Q3 operational progress
Key points
- Anteris continued enrolment across multiple countries for its global PARADIGM study and secured key European and Australian clearances.
- The company assumed occupancy of a Minnesota production facility and appointed a new chief financial officer.
- Expansion of site operations supports preparation to commercialize its DurAVR heart valve and ComASUR delivery system.
Anteris Technologies (ASX:AVR) reported third-quarter operational progress for the period ended Sept. 30, driven by global heart-valve trial activity.
The company expanded clinical sites into Canada and France while maintaining ongoing enrolment across the United States, Denmark, and the Netherlands.
“Q3 saw continued progress on multiple fronts. The PARADIGM Trial recruitment is advancing along with capacity expansion in line with our clinical and commercial plan. The company also brought in some key hires to strengthen our operating model and future capabilities,” said Anteris Technologies Vice Chairman and CEO Wayne Paterson.
Anteris stated that occupying its Northcross facility in Brooklyn Park, Minnesota, on Sept. 1 provides extra capacity to manufacture DurAVR valves.
Following the announcement, the Anteris share price was unchanged at $8.50.
Subsequent to quarter-end, the company secured regulatory clearance from Germany’s BfArM alongside Australian ethics and clinical trial notifications.
Brent Moen formally assumed duties as CFO on Sept. 11 to support governance priorities ahead of planned product commercialisation.
